Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AB Science
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed multiple myeloma with a t (4; 14) translocation by FISH and PCR, expressing or not expressing FGFR3 identified by FACS
Patients with Multiple Myeloma progressing or relapsing after at least two prior therapies (including conventional chemotherapy and/or high dose therapy) or who get a reduction of M-protein less than 75% within 3 months after a high dose treatment (Melphalan 200mg/m2) or after the plateau obtained for 3 months duration following to a conventional chemotherapy
Patient with rapidly progressive disease with cytopenia and / or renal failure have to be stabilized with chemotherapy (if possible 3 cycles of VTD ( Bortezomib/Thalidomide/dexamethasone) or high dose Melphalan regimen followed by a 4 weeks washout period before the inclusion in the study.
Patients must have a clearly detectable and quantifiable monoclonal M- component value (\>5 g/l) in the serum and / or urine light chain excretion (\>0,5 g/d)
You may not be if
Prior corticosteroids within two weeks before enrolment
Prior local irradiation within two weeks before enrolment
Prior experimental or standard treatment (other than steroids and local irradiation) within 30 days before enrolment